Literature DB >> 23847228

Systemic mycoplasmosis with dystocia and abortion in a North American bison (Bison bison) herd.

Karen B Register1, Murray R Woodbury, Jennifer L Davies, Jessie D Trujillo, José Perez-Casal, Patrick H Burrage, Edward G Clark, M Claire Windeyer.   

Abstract

The current study describes a fatal Mycoplasma bovis infection in a North American bison (Bison bison) cow and her aborted fetus in a herd suffering unusual mortality associated with dystocia and abortion. Postmortem evaluation of the subject case found severe caseonecrotic bronchopneumonia, chronic fibrinous pleuritis and pulmonary sequestra, foci of caseous necrosis in the kidneys, and necrotizing endometritis and placentitis. Histologic findings in the maternal tissues include endometrial and placental necrotizing vasculitis and changes in the lung similar to those previously described for M. bovis-associated pneumonia in feedlot bison. Gross and microscopic lesions were not observed in the fetus. Maternal lung, uterus, kidney, and placenta as well as fetal lung and kidney were positive for M. bovis by polymerase chain reaction (PCR) as were the Mycoplasma-like colonies cultured from these tissues. The presence of M. bovis in maternal and fetal tissues was further demonstrated using nucleic acid extracts in a pan-Mycoplasma SYBR Green PCR assay targeting the 16S-23S ribosomal RNA spacer region with post-PCR dissociation curve analysis and sequencing of the resulting amplicons. Immunohistochemistry (IHC) testing on maternal lung and uterine caruncle was strongly positive for M. bovis antigen. A variety of methods, including culture, PCR, and IHC, failed to identify other bacterial or viral pathogens in any of the tissues evaluated. These data are the first to implicate M. bovis as a cause of placentitis and abortion in bison.

Entities:  

Keywords:  Abortion; Mycoplasma bovis; bison

Mesh:

Substances:

Year:  2013        PMID: 23847228     DOI: 10.1177/1040638713495029

Source DB:  PubMed          Journal:  J Vet Diagn Invest        ISSN: 1040-6387            Impact factor:   1.279


  6 in total

1.  Evaluation of enzyme-linked immunosorbent assays for detection of Mycoplasma bovis-specific antibody in bison sera.

Authors:  Karen B Register; Randy E Sacco; Steven C Olsen
Journal:  Clin Vaccine Immunol       Date:  2013-07-10

2.  Multi-locus sequence typing of Mycoplasma bovis to assess its genetic diversity from 2009 to 2018 in Ningxia Hui Autonomous Region, China.

Authors:  Yanan Guo; Haifeng Luo; Shuqiang Guo; Yuanyuan Lei; Yong Li; Shenghu He
Journal:  BMC Vet Res       Date:  2020-11-23       Impact factor: 2.741

3.  Serological evidence for historical and present-day exposure of North American bison to Mycoplasma bovis.

Authors:  Karen B Register; Margaret Parker; Kelly A Patyk; Steven J Sweeney; William D Boatwright; Lee C Jones; Murray Woodbury; David L Hunter; John Treanor; Marshall Kohr; Robert G Hamilton; Todd K Shury; Pauline Nol
Journal:  BMC Vet Res       Date:  2021-01-07       Impact factor: 2.741

4.  Mycoplasma ovipneumoniae--a primary cause of severe pneumonia epizootics in the Norwegian Muskox (Ovibos moschatus) population.

Authors:  Kjell Handeland; Torstein Tengs; Branko Kokotovic; Turid Vikøren; Roger D Ayling; Bjarne Bergsjø; Olöf G Sigurðardóttir; Tord Bretten
Journal:  PLoS One       Date:  2014-09-08       Impact factor: 3.240

5.  Antimicrobial activity of bovine NK-lysin-derived peptides on Mycoplasma bovis.

Authors:  Rohana P Dassanayake; Shollie M Falkenberg; Karen B Register; Daniel Samorodnitsky; Eric M Nicholson; Timothy A Reinhardt
Journal:  PLoS One       Date:  2018-05-17       Impact factor: 3.240

6.  Mycoplasma bovis Infections in Free-Ranging Pronghorn, Wyoming, USA.

Authors:  Jennifer L Malmberg; Donal O'Toole; Terry Creekmore; Erika Peckham; Hally Killion; Madison Vance; Rebecca Ashley; Marguerite Johnson; Christopher Anderson; Marce Vasquez; Douglas Sandidge; Jim Mildenberger; Noah Hull; Dan Bradway; Todd Cornish; Karen B Register; Kerry S Sondgeroth
Journal:  Emerg Infect Dis       Date:  2020-12       Impact factor: 6.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.